AnaptysBio (NASDAQ: ANAB) CMO logs RSU vesting and tax sale of shares

Rhea-AI Filing Summary

AnaptysBio Chief Medical Officer Paul F. Lizzul reported routine equity activity involving vested RSUs and a related share sale. On January 3, 2026, 10,555 restricted stock units were converted into the same number of shares of common stock at an exercise price of $0, increasing his directly held common stock to 37,522 shares. Each RSU represents the right to receive 1 share of common stock for no cash consideration.

On January 5, 2026, he sold 4,219 shares of common stock at $43.26 per share, leaving him with 33,303 directly owned shares. According to the disclosure, this sale was executed solely to cover tax withholding obligations from the RSU vesting through a "sell to cover" transaction and is described as not a discretionary transaction. The RSUs vest 25% annually starting January 3, 2025, subject to his continued service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lizzul Paul F.

(Last) (First) (Middle)

C/O ANAPTYSBIO, INC.

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/03/2026		M		10,555	A	(1)	37,522	D
Common Stock	01/05/2026		S(2)		4,219	D	$43.26	33,303	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	01/03/2026		M			10,555	(3)	(3)	Common Stock	10,555	$0	21,110	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

2. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

3. The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Eric Loumeau, Attorney-in-Fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did AnaptysBio (ANAB) disclose for Paul F. Lizzul?

The filing shows that Paul F. Lizzul, Chief Medical Officer of AnaptysBio, Inc., reported the vesting and settlement of 10,555 restricted stock units into common shares on January 3, 2026, followed by a sale of 4,219 shares of common stock on January 5, 2026.

How many AnaptysBio (ANAB) shares did the CMO sell and at what price?

On January 5, 2026, the Chief Medical Officer sold 4,219 shares of AnaptysBio common stock at a price of $43.26 per share, as reported in the non-derivative transaction table.

Why did the AnaptysBio CMO sell shares in this Form 4 filing?

The disclosure states that the sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations arising from the vesting and settlement of RSUs. It further notes that the sale was a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.

What are the terms of the RSUs reported by the AnaptysBio CMO?

Each restricted stock unit (RSU) represents a contingent right to receive 1 share of AnaptysBio common stock upon settlement for no cash consideration. The RSUs vest as to 25% of the total units annually, commencing on January 3, 2025, until fully vested, subject to the reporting person continuing to provide service on each vesting date.

How many AnaptysBio shares does the CMO own after these transactions?

After the RSU conversion and subsequent sale, the Form 4 reports that the Chief Medical Officer beneficially owns 33,303 shares of AnaptysBio common stock directly as of the last reported transaction.

What derivative security is involved in this AnaptysBio (ANAB) Form 4?

The derivative security reported is a restricted stock unit (RSU). On January 3, 2026, 10,555 RSUs were exercised at an exercise price of $0, corresponding to 10,555 underlying shares of common stock. Following this transaction, 21,110 RSUs remained beneficially owned directly.